Amarin Corporation plc (NASDAQ:AMRN) today reported an overview of
new data relating to VASCEPA®/VAZKEPA (icosapent ethyl) presented
at ESC Congress 2021, organized by the European Society of
Cardiology (ESC), taking place virtually from August 27 – August
30, 2021.
“We are delighted to have this collection of
data in support of VASCEPA/VAZKEPA’s differentiated positioning in
treating patients at risk for major adverse cardiovascular events
presented at ESC 2021 before an audience of global cardiovascular
specialists,” said Karim Mikhail, Amarin’s president and chief
executive officer. “As we approach the European launch of VAZKEPA,
it is particularly important that such clinical and scientific
findings are reported. Collectively, these data are building a body
of clinical evidence that elucidate and evolve our understanding of
the potential mechanisms of action and supporting role of the
therapy in alleviating the burden of the worldwide public health
crisis caused by cardiovascular disease.”
ESC 2021 Guidelines on Cardiovascular
Disease Prevention in Clinical Practice
Amarin also reports that the ESC released their 2021 Guidelines
on cardiovascular disease prevention in clinical practice, which
includes icosapent ethyl (VAZKEPA) as a new recommendation to
address high-risk cardiovascular patients with elevated
triglycerides (135-499 mg/dL) despite statin treatment and
lifestyle measures. The classification is a Level B recommendation,
which reflects a relatively high weight of scientific evidence
under ESC standards. This guideline was developed by the Task Force
for cardiovascular disease prevention in clinical practice with
representatives of the ESC and 12 medical societies with the
special contribution of the European Association of Preventive
Cardiology (EAPC). With this new inclusion, VASCEPA/VAZKEPA is now
included in 20 separate guidelines, scientific statements, or
consensus statements.
“The expanding inclusion of VASCEPA/VAZKEPA in global clinical
practice guidelines further validates the important role our IPE
plays in addressing cardiovascular risk. This new inclusion in the
ESC guidelines is particularly timely as we are planning our
initial country launch in Europe in September,” added Mr.
Mikhail.
Key data presented at ESC Congress
2021
Late Breaking Science Presentations
“Reduction in Ischemic Events, Including
Cardiovascular Mortality, with Icosapent Ethyl in Patients with
Prior Myocardial Infarction: REDUCE-IT PRIOR MI” –
presented on behalf of all authors by Deepak L. Bhatt, M.D.,
M.P.H., Brigham and Women’s Hospital.
Highlights: The investigators
concluded that, “Icosapent ethyl 4 g/day significantly reduced
first and total primary endpoints of 5-point major adverse
cardiovascular event (MACE), comprised of CV death, MI (myocardial
infarction), stroke, coronary revascularization, and
hospitalization for unstable angina by 26% and 35%, respectively,
in REDUCE-IT patients with prior MI (P=0.00001 and P=0.0000001,
respectively). Icosapent ethyl led to generally robust reductions
across the prespecified hierarchy of secondary endpoints, and in
sudden cardiac death and cardiac arrest. The benefits of icosapent
ethyl in patients with prior MI were consistent in those with or
without a history or prior revascularization.”
For more information on this Late Breaking
Science session, see Amarin’s previously issued press release,
which is available here.
“Icosapent Ethyl (IPE) Versus Placebo in
People Exposed to COVID-19: The Main Results of
PREPARE-IT-1” – presented on behalf of all authors by
Rafael Diaz, M.D., Estudios Cardiologicos Latinoamerica (ECLA),
Rosario, Argentina.
Highlights: These data
represent the first presentation of the topline final results from
the PREPARE-IT 1 study, which was an investigator-initiated trial
(IIT) of approximately 2000 SARS CoV-2 negative, high-risk
healthcare and other public workers in Argentina. In this study,
subjects were randomized 1:1 to receive IPE or placebo and received
a loading dose of 8 grams per day on days 1-3 and 4 grams per day
on days 4-60. The primary endpoint is the percentage of subjects
positive for SARS-CoV-2 through day 60.
While the results of the PREPARE-IT 1 study in
Argentina did not meet the primary and/or other endpoints studied,
we believe it is valuable for Amarin to support pilot
investigator-initiated trials (IITs) of this nature to determine
the safety and potential efficacy of VASCEPA/VAZKEPA (icosapent
ethyl) in a diverse group of at-risk populations.
PREPARE-IT 1 is part of a series of IITs
evaluating VASCEPA’s potential benefit in preventing and/or
treating COVID-19. Amarin is looking forward to the results of the
PREPARE-IT 2 and MITIGATE trials, as the totality of the data will
advise the various clinical and regulatory pathways Amarin may
explore for the potential use of VASCEPA as an adjunctive treatment
to reduce the risk of infection and/or as a treatment for
COVID-19.
The results of this study have no relationship
to or bearing on the FDA-approved indication for VASCEPA to reduce
CV risk when added to a statin.
e-Poster Presentations
“Cardiovascular benefits outweigh risks
in patients with atrial fibrillation in REDUCE-IT (Reduction of
Cardiovascular Events with Icosapent Ethyl-Intervention
Trial)” – presented on behalf of all authors by Brian
Olshansky, M.D., University of Iowa.
Highlights: Post hoc analyses
of REDUCE-IT subgroups with baseline atrial fibrillation and/or
flutter (AF/F) history or in-study endpoints of AF/F
hospitalization evaluated subjects with prior baseline AF/F history
identified from medical history. In-study AF/F was included within
a broader prespecified adjudicated endpoint of “cardiac arrhythmia
requiring hospitalization ≥24 hours,” under which the type of
arrhythmia (e.g., AF/F) was specified. AF/F events not meeting
endpoint criteria remained in the safety data set.
The study authors concluded that, when treated
with icosapent ethyl (IPE), REDUCE-IT patients with atrial
fibrillation history or in-study atrial fibrillation
hospitalization endpoints had greater CV risk, but similar relative
risk reduction in primary, key secondary, and fatal or nonfatal
stroke endpoints.
“Omega-3 Fatty Acids Differentially
Alter the Expression of Detoxification Enzymes and Nitric Oxide
Bioavailability in Endothelial Cells during IL-6 Exposure”
– presented on behalf of all authors by R. Preston Mason, Ph.D.,
Brigham and Women’s Hospital.
Highlights: Endothelial cell
(EC) dysfunction is causally related to abnormal vasodilation and
contributes to increased risk for atherothrombotic disease.
Hallmark features of EC dysfunction include reduced nitric oxide
(NO) bioavailability and increased production of the cytotoxic
peroxynitrite anion (ONOO-) as a result of nitic oxide synthase
(eNOS) uncoupling and oxidative stress. This study compared the
effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) on endothelial function and detoxification enzyme expression
under conditions of inflammation with IL-6.
The study concluded that, “EPA and DHA
differentially influenced NO bioavailability and expression of ROS
(reactive oxygen species) detoxification proteins, including
peroxiredoxin and superoxide isoforms. The net benefits of EPA on
eNOS function and free radical detoxification may contribute to
reduced atherothrombotic risk compared to DHA.”
“Omega-3 Fatty Acids Differentially
Reduce Expression of Neutrophil Degranulation-Associated Proteins
in Endothelial Cells during IL-6 Exposure” – presented on
behalf of all authors by R. Preston Mason, Ph.D., Brigham and
Women’s Hospital.
Highlights: It has been shown
that when challenged with pro-inflammatory stimuli, endothelial
cells can produce signals (IL-6) that induce neutrophil
degranulation. The goal of this study was to use proteomic
approaches to compare the effects of EPA and DHA on protein
expression mediating the neutrophil degranulation pathway,
including platelet endothelial cell adhesion molecule 1 (PECAM 1),
as determined by gene set enrichment analysis (GSEA).
The study results showed that “EPA and DHA
differentially modulated expression of proteins linked to
neutrophil degranulation. The distinct effects of EPA on protein
expression may contribute to reduced inflammation associated with
atherosclerosis compared to DHA."
“Eicosapentaenoic Acid (EPA) Inhibits
Lipopolysaccharide (LPS)-induced Nitrite Production and Cytokine
Release from J774 Macrophages” – presented on behalf of
all authors by R. Preston Mason, Ph.D., Brigham and Women’s
Hospital.
Highlights: The study concluded
that EPA reduced macrophage activation in a dose-dependent manner
as evidenced by decreased nitrite production and cytokine release
similar to other anti-inflammatory agents, and that “these findings
indicate a novel effect of EPA on mechanisms of inflammation
associated with vascular disease.”
“Characteristics and prognosis of
patients with elevated triglycerides in acute myocardial
infarction: observational data from a large database over a
17-years period” – presented on behalf of all authors by
Michel Farnier, M.D., University of Bourgogne Franche-Comté -
Dijon, France.
Highlights: Using a large
database of a regional registry, the study authors aimed to address
the prevalence, characteristics and prognosis of patients with
elevated triglycerides (TG) hospitalized for an acute myocardial
infarction (MI). From the multicenter database (RICO survey), all
consecutive patients hospitalized for an acute MI (2001-2017) and
alive at discharge were included. Patients with TG > 500 mg/dL,
lost to follow-up (FU), or under chronic fibrate treatment were
excluded. Patients with high TG (> 200 mg/dL) on admission were
compared to those with TG ≤ 200 mg/dL. Endpoints were recurrent
ischemic events (i.e., recurrent MI, angina, unstable angina,
stroke or urgent revascularization (PCI or CABG)) at 1-year FU.
The study results from this large
population-based cohort showed that “elevated TG are common in
acute MI, and associated with residual risk of recurrent ischemic
events, beyond traditional prognostic markers. These data may help
to identify candidates for targeted therapies to reduce recurrent
ischemic risk after MI.”
All analyses highlighted above were supported or funded by
Amarin.
Additional REDUCE-IT and icosapent ethyl
(EPA)-related topics will be presented at ESC Congress 2021 and can
be found at https://digital-congress.escardio.org/ESC-Congress (if
registered to ESC Congress).
About Amarin
Amarin is an innovative pharmaceutical company
leading a new paradigm in cardiovascular disease management. From
our scientific research foundation to our focus on clinical trials,
and now our commercial expansion, we are evolving and growing
rapidly. Amarin has offices in Bridgewater, New Jersey in the
United States, Dublin in Ireland, and Zug in Switzerland as well as
commercial partners and suppliers around the world. We are
committed to rethinking cardiovascular risk through the advancement
of scientific understanding of the impact on society of significant
residual risk that exists beyond traditional therapies, such as
statins for cholesterol management.
About Cardiovascular Risk
Cardiovascular disease is the number one cause
of death in the world. In the United States alone, cardiovascular
disease results in 859,000 deaths per year.1 And the number of
deaths in the United States attributed to cardiovascular disease
continues to rise. In addition, in the United States there are
605,000 new and 200,000 recurrent heart attacks per year
(approximately 1 every 40 seconds). Stroke rates are 795,000 per
year (approximately 1 every 40 seconds), accounting for 1 of every
19 U.S. deaths. In aggregate, in the United States alone, there are
more than 2.4 million major adverse cardiovascular events per year
from cardiovascular disease or, on average, 1 every 13 seconds.
Controlling bad cholesterol, also known as
LDL-C, is one way to reduce a patient’s risk for cardiovascular
events, such as heart attack, stroke or death. However, even with
the achievement of target LDL-C levels, millions of patients still
have significant and persistent risk of cardiovascular events,
especially those patients with elevated triglycerides. Statin
therapy has been shown to control LDL-C, thereby reducing the risk
of cardiovascular events by 25-35%.2 Significant
cardiovascular risk remains after statin therapy. People with
elevated triglycerides have 35% more cardiovascular events compared
to people with normal (in range) triglycerides taking
statins.3,4,5
About REDUCE-IT®
REDUCE-IT was a global cardiovascular outcomes
study designed to evaluate the effect of VASCEPA in adult patients
with LDL-C controlled to between 41-100 mg/dL (median baseline 75
mg/dL) by statin therapy and various cardiovascular risk factors
including persistent elevated triglycerides between 135-499 mg/dL
(median baseline 216 mg/dL) and either established cardiovascular
disease (secondary prevention cohort) or diabetes mellitus and at
least one other cardiovascular risk factor (primary prevention
cohort).
REDUCE-IT, conducted over seven years and
completed in 2018, followed 8,179 patients at over 400 clinical
sites in 11 countries with the largest number of sites located
within the United States. REDUCE-IT was conducted based on a
special protocol assessment agreement with FDA. The design of the
REDUCE-IT study was published in March 2017
in Clinical Cardiology.6 The primary
results of REDUCE-IT were published in The New England
Journal of Medicine in November 2018.7 The total
events results of REDUCE-IT were published in
the Journal of the American College of
Cardiology in March 2019.8 These and other
publications can be found in the R&D section on the company’s
website at www.amarincorp.com.
About
VASCEPA® (icosapent ethyl)
Capsules
VASCEPA (icosapent ethyl) capsules are the
first-and-only prescription treatment approved by the U.S. Food and
Drug Administration (FDA) comprised solely of the active
ingredient, icosapent ethyl (IPE), a unique form of
eicosapentaenoic acid. VASCEPA was launched in the United States in
January 2020 as the first and only drug approved by the U.S. FDA
for treatment of the studied high-risk patients with persistent
cardiovascular risk after statin therapy. VASCEPA was initially
launched in the United States in 2013 based on the drug’s initial
FDA-approved indication for use as an adjunct therapy to diet to
reduce triglyceride levels in adult patients with severe (≥500
mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been
prescribed over ten million times. VASCEPA is covered by most major
medical insurance plans. In addition to the United States, VASCEPA
is approved and sold in Canada, Lebanon and the United Arab
Emirates. In Europe, in March 2021 marketing authorization was
granted to icosapent ethyl in the European Union for the reduction
of risk of cardiovascular events in patients at high cardiovascular
risk, under the brand name VAZKEPA.
Indications and Limitation of Use (in the United
States)VASCEPA is indicated:
- As an adjunct to maximally
tolerated statin therapy to reduce the risk of myocardial
infarction, stroke, coronary revascularization and unstable angina
requiring hospitalization in adult patients with elevated
triglyceride (TG) levels (≥ 150 mg/dL) and
- established cardiovascular disease
or
- diabetes mellitus and two or more
additional risk factors for cardiovascular disease.
- As an adjunct to diet to reduce TG
levels in adult patients with severe (≥ 500 mg/dL)
hypertriglyceridemia.
The effect of VASCEPA on the risk for
pancreatitis in patients with severe hypertriglyceridemia has not
been determined.
Important Safety
Information
- VASCEPA is contraindicated in
patients with known hypersensitivity (e.g., anaphylactic reaction)
to VASCEPA or any of its components.
- VASCEPA was associated with an
increased risk (3% vs 2%) of atrial fibrillation or atrial flutter
requiring hospitalization in a double-blind, placebo-controlled
trial. The incidence of atrial fibrillation was greater in patients
with a previous history of atrial fibrillation or atrial
flutter.
- It is not known whether patients
with allergies to fish and/or shellfish are at an increased risk of
an allergic reaction to VASCEPA. Patients with such allergies
should discontinue VASCEPA if any reactions occur.
- VASCEPA was associated with an
increased risk (12% vs 10%) of bleeding in a double-blind,
placebo-controlled trial. The incidence of bleeding was greater in
patients receiving concomitant antithrombotic medications, such as
aspirin, clopidogrel or warfarin.
- Common adverse reactions in the
cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent
than placebo): musculoskeletal pain (4% vs 3%), peripheral edema
(7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial
fibrillation (5% vs 4%).
- Common adverse reactions in the
hypertriglyceridemia trials (incidence >1% more frequent
than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs
0.3%).
- Adverse events may be reported by
calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
- Patients receiving VASCEPA and
concomitant anticoagulants and/or anti-platelet agents should be
monitored for bleeding.
Key clinical effects of VASCEPA on major adverse
cardiovascular events are included in the Clinical Studies section
of the prescribing information for VASCEPA as set forth below:
Effect of VASCEPA on Time to First
Occurrence of Cardiovascular Events in Patients with
Elevated Triglyceride levels and Other Risk Factors for
Cardiovascular Disease in REDUCE-IT
|
VASCEPA |
Placebo |
VASCEPA vs Placebo |
N = 4089n (%) |
Incidence Rate (per 100 patient
years) |
N = 4090n (%) |
Incidence Rate (per 100 patient
years) |
Hazard Ratio (95% CI) |
Primary composite endpoint |
Cardiovascular death, myocardial infarction, stroke, coronary
revascularization, hospitalization for unstable angina (5-point
MACE) |
705(17.2) |
4.3 |
901(22.0) |
5.7 |
0.75(0.68, 0.83) |
Key secondary composite endpoint |
Cardiovascular death, myocardial infarction, stroke (3-point
MACE) |
459(11.2) |
2.7 |
606(14.8) |
3.7 |
0.74(0.65, 0.83) |
Other secondary endpoints |
Fatal or non-fatal myocardial infarction |
250(6.1) |
1.5 |
355(8.7) |
2.1 |
0.69(0.58, 0.81) |
Emergent or urgent coronary revascularization |
216(5.3) |
1.3 |
321(7.8) |
1.9 |
0.65(0.55, 0.78) |
Cardiovascular death [1] |
174(4.3) |
1.0 |
213(5.2) |
1.2 |
0.80(0.66, 0.98) |
Hospitalization for unstable angina [2] |
108(2.6) |
0.6 |
157(3.8) |
0.9 |
0.68(0.53, 0.87) |
Fatal or non-fatal stroke |
98(2.4) |
0.6 |
134(3.3) |
0.8 |
0.72(0.55, 0.93) |
[1] Includes adjudicated cardiovascular deaths and deaths of
undetermined causality.[2] Determined to be caused by myocardial
ischemia by invasive/non-invasive testing and requiring emergent
hospitalization. |
FULL U.S. FDA-APPROVED
VASCEPA PRESCRIBING
INFORMATION CAN BE FOUND
AT WWW.VASCEPA.COM.
Forward-Looking Statements
This press release contains forward-looking
statements which are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995, including
beliefs about the world-wide market potential for VASCEPA;
expectations regarding financial metrics and performance such as
prescription growth, revenue growth, operating expenses, inventory
purchases, and managed care coverage for VASCEPA, including the
impact of the COVID-19 pandemic, the disappointing outcome of
patent litigation and the launch of generic competition on these
metrics; beliefs that Amarin is well positioned to deliver on its
goals to grow VASCEPA in the U.S. and beyond; beliefs about patient
needs for VASCEPA; effects of the COVID-19 pandemic on Amarin's
operations and on the healthcare industry more broadly, which
effects continue to be fluid; beliefs that Amarin's strategy for
reducing the effects of cardiovascular disease is sound and that
Amarin is efficiently reaching physicians, payors, pharmacists and
patients; plans for Amarin's go-to-market model; the timing and
outcome of regulatory reviews, recommendations and approvals and
related reimbursement decisions and commercial launches in Europe,
the China region and elsewhere; plans for Amarin's expected launch
of VASCEPA directly in major markets in Europe, directly and
indirectly; beliefs about the cardioprotective and other benefits
of VASCEPA; beliefs about the strength of data in market access
dossiers and other reports; expectations for the timing,
effectiveness and outcome of promotional activities, including
patient-oriented campaigns, conference and posted presentations and
education of healthcare professionals; commercial and international
expansion, prescription growth and revenue growth and future
revenue levels, including the contributions of sales
representatives and the new leadership team; beliefs that Amarin's
current resources are sufficient to fund projected operations;
ongoing patent litigation efforts; and the impact of the COVID-19
pandemic on all of the forgoing. These forward-looking statements
are not promises or guarantees and involve substantial risks and
uncertainties. Amarin's ability to effectively commercialize
VASCEPA and maintain or grow market share will depend in part on
Amarin’s ability to continue to effectively finance its business,
VASCEPA approval in geographies outside the U.S., efforts of third
parties, Amarin’s ability to create and increase market demand for
VASCEPA through education, marketing and sales activities, to
achieve broad market acceptance of VASCEPA, to receive adequate
levels of reimbursement from third-party payers, to develop and
maintain a consistent source of commercial supply at a competitive
price, to comply with legal and regulatory requirements in
connection with the sale and promotion of VASCEPA and to secure,
maintain and defend its patent protection for VASCEPA. Among the
factors that could cause actual results to differ materially from
those described or projected herein include the following: the
possibility that VASCEPA may not receive regulatory approval in the
China region or other geographies on the expected timelines or at
all, the risk that additional generic versions of VASCEPA will
enter the market and that generic versions of VASCEPA will achieve
greater market share and more commercial supply than anticipated,
particularly in light of the recent and disappointing outcome of
Amarin's litigation against two generic drug companies and
subsequent requests for appeal; the risk that the scope and
duration of the COVID-19 pandemic will continue to impact access to
and sales of VASCEPA; the risk that Amarin has overestimated the
market potential for VASCEPA in the U.S., Europe and other
geographies; risks associated with Amarin's expanded enterprise;
uncertainties associated generally with research and development,
clinical trials and related regulatory approvals; the risk that
sales may not meet expectations and related cost may increase
beyond expectations; the risk that patents may be determined to not
be infringed or not be valid in patent litigation and applications
may not result in issued patents sufficient to protect the VASCEPA
franchise. A further list and description of these risks,
uncertainties and other risks associated with an investment in
Amarin can be found in Amarin's filings with the U.S. Securities
and Exchange Commission, including Amarin’s quarterly report on
Form 10-Q for the quarter ended June 30, 2021, filed on or about
the date hereof. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date they are made. Amarin undertakes no
obligation to update or revise the information contained in its
forward looking statements, whether as a result of new information,
future events or circumstances or otherwise. Amarin’s
forward-looking statements do not reflect the potential impact of
significant transactions the company may enter into, such as
mergers, acquisitions, dispositions, joint ventures or any material
agreements that Amarin may enter into, amend or terminate.
Availability of Other Information About
Amarin
Investors and others should note that Amarin
communicates with its investors and the public using the company
website (www.amarincorp.com), the investor relations website
(investor.amarincorp.com), including but not limited to investor
presentations and investor FAQs, Securities and Exchange Commission
filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could
be deemed to be material information. As a result, Amarin
encourages investors, the media, and others interested in Amarin to
review the information that is posted on these channels, including
the investor relations website, on a regular basis. This list of
channels may be updated from time to time on Amarin’s investor
relations website and may include social media channels. The
contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.
Amarin Contact InformationInvestor
Inquiries:Investor RelationsAmarin Corporation plcIn U.S.:
+1 (908) 719-1315IR@amarincorp.com (investor inquiries)
Solebury Troutamarinir@troutgroup.com
Media Inquiries:CommunicationsAmarin
Corporation plcIn U.S.: +1 (908)
892-2028PR@amarincorp.com (media inquiries)
AMARIN, REDUCE-IT, VASCEPA and VAZKEPA are
trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a
registered trademark in Europe and other countries and regions and
is pending registration in the United States.
1 American Heart Association. Heart Disease and
Stroke Statistics—2020 Update: A Report From the American Heart
Association. Circulation. 2020;141:e139-e596.2 Ganda OP, Bhatt DL,
Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in
hypertriglyceridemia management. J Am Coll Cardiol.
2018;72(3):330-343.3 Budoff M. Triglycerides and triglyceride-rich
lipoproteins in the causal pathway of cardiovascular disease. Am J
Cardiol. 2016;118:138-145.4 Toth PP, Granowitz C, Hull M, et al.
High triglycerides are associated with increased cardiovascular
events, medical costs, and resource use: A real-world
administrative claims analysis of statin-treated patients with high
residual cardiovascular risk. J Am Heart Assoc.
2018;7(15):e008740.5 Nordestgaard BG. Triglyceride-rich
lipoproteins and atherosclerotic cardiovascular disease - New
insights from epidemiology, genetics, and biology. Circ Res.
2016;118:547-563.6 Bhatt DL, Steg PG, Brinton E, et al., on behalf
of the REDUCE-IT Investigators. Rationale and Design of REDUCE‐IT:
Reduction of Cardiovascular Events with Icosapent
Ethyl–Intervention Trial. Clin Cardiol. 2017;40:138-148.7 Bhatt DL,
Steg PG, Miller M, et al., on behalf of the REDUCE-IT
Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl
for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.8 Bhatt DL,
Steg PG, Miller M, et al., on behalf of the REDUCE-IT
investigators. Effects of Icosapent Ethyl on Total Ischemic Events:
From REDUCE-IT. J Am Coll Cardiol. 2019;73:2791-2802.
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024